38 results on '"Rea F"'
Search Results
2. ANTIDIABETIC DRUG THERAPY AND SURVIVAL IN ELDERLY FRAIL PATIENTS. REAL-LIFE EVIDENCE FROM ITALY
- Author
-
Savare, L, Rea, F, Valsassina, V, Corrao, G, Mancia, G, Savare, L, Rea, F, Valsassina, V, Corrao, G, and Mancia, G
- Published
- 2023
3. THE IMPACT OF RENAL DENERVATION PROCEDURE ON THE USE OF ANTIHYPERTENSIVE DRUGS. A REAL-LIFE INVESTIGATION FROM ITALY
- Author
-
Rea, F, Morabito, G, Savare, L, Corrao, G, Mancia, G, Rea, F, Morabito, G, Savare, L, Corrao, G, and Mancia, G
- Published
- 2023
4. USE OF INITIAL AND SUBSEQUENT ANTIHYPERTENSIVE COMBINATION TREATMENT IN THE CLINICAL PRACTICE. EVIDENCE FROM A POPULATION-BASED INVESTIGATION IN ITALY
- Author
-
Savare, L, Rea, F, Corrao, G, Mancia, G, Savare, L, Rea, F, Corrao, G, and Mancia, G
- Published
- 2023
5. TREATMENT STRATEGIES AND ADHERENCE TO THE TRIPLE COMBINATION OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, A CALCIUM-CHANNEL BLOCKER, AND A DIURETIC
- Author
-
Rea, F, Morabito, G, Savaré, L, Pathak, A, Corrao, G, Mancia, G, Rea, F, Morabito, G, Savaré, L, Pathak, A, Corrao, G, and Mancia, G
- Published
- 2023
6. Evaluating sources of bias in observational studies
- Author
-
Corrao, G, Rea, F, Mancia, G, Corrao G., Rea F., Mancia G., Corrao, G, Rea, F, Mancia, G, Corrao G., Rea F., and Mancia G.
- Published
- 2021
7. Lessons from COVID-19 mortality data across countries
- Author
-
Corrao, G, Rea, F, Blangiardo, G, Corrao G., Rea F., Blangiardo G. C., Corrao, G, Rea, F, Blangiardo, G, Corrao G., Rea F., and Blangiardo G. C.
- Abstract
OBJECTIVE: Several online sources provide up-to-date open-access data on numbers, rates and proportions of COVID-19 deaths. Our article aims of comparing and interpreting between-country trends of mortality rate, case-fatality and all-cause excess mortality. METHODS: We used data from open databases (Our World in Data mostly) for comparing mortality of eleven western countries (Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, UK, USA). Between-country trends in mortality rate and case-fatality (both including deaths for COVID-19 as numerator and therefore labelled as COVID-19 mortality metrics) and all-cause excess mortality (i.e. observed deaths during the epidemic compared with those expected based on mortality in the same periods of previous years) were compared. RESULTS: Although Belgium ranks first in mortality from COVID-19 (possibly due to the broadest criterion for attributing a death to COVID-19), it does not rank first for all-cause excess mortality. Conversely, compared with Belgium, the UK, Italy and Spain have reported lower COVID-19 mortality (possibly due to the narrower definitions for a COVID-19 death) but higher all-cause excess mortality. Germany and Austria are the unique countries for which COVID-19 mortality, case-fatality and all-cause excess mortality consistently exhibited the lowest rates. CONCLUSION: Between-country heterogeneity of COVID-19 mortality metrics could be largely explained by differences of criteria for attributing a death to COVID-19; in age/comorbidity structures; in policies for identifying asymptomatic people affected from SARS-CoV-2 infection. All-cause excess mortality is recommended as a more reliable metric for comparing countries.
- Published
- 2021
8. Use of initial and subsequent antihypertensive combination treatment in the last decade: analysis of a large Italian database
- Author
-
Savaré, L, Rea, F, Corrao, G, Mancia, G, Savaré, Laura, Rea, Federico, Corrao, Giovanni, Mancia, Giuseppe, Savaré, L, Rea, F, Corrao, G, Mancia, G, Savaré, Laura, Rea, Federico, Corrao, Giovanni, and Mancia, Giuseppe
- Abstract
Objective:The aim of the study was to assess the use of antihypertensive combination treatment, both as the initial and as a subsequent therapeutic step, in a large Italian population.Methods:The residents of the Lombardy Region (Italy), aged 40 years or older, who were newly treated with antihypertensive drugs during 2012, 2015 and 2018 were identified and the drug treatment strategy (monotherapy and combination of two, three and more than three antihypertensive drugs) was assessed at treatment initiation, and after 6 months, 1, 2, and 3 years of treatment. Data were also analysed after stratification for demographic and clinical categories.Results:About 100 000 patients were identified for each cohort. Monotherapy was the most common initial treatment strategy (75%), followed by two-drug single-pill combination (16%), two-drug free combination (6%), and combination of at least three drugs (3%). Use of two and three or more antihypertensive drugs increased during follow-up and reached about 32% (two drugs) and 11% (>2 drugs) of the patients after 3 years from treatment initiation. Among patients prescribed a two-drug combination, the single-pill was the most common approach, whereas the use of the three-drug single-pill combination was extremely rare. There were no substantial differences in the use of combination treatment between the three cohorts and the results were similar in all demographic and clinical categories.Conclusion:Our data show that in a real-life population use of antihypertensive drug combinations is low. They also show that, contrary to guideline recommendations, antihypertensive combination treatment did not show any noticeable increase in recent years.
- Published
- 2022
9. TWO-DRUG FIXED-DOSE COMBINATION AS INITIAL ANTIHYPERTENSIVE TREATMENT STRATEGY CONFERS HIGHER MEDICATION ADHERENCE COMPARED TO MONOTHERAPY
- Author
-
Rea, F, Savaré, L, Corrao, G, Mancia, G, Rea, F, Savaré, L, Corrao, G, and Mancia, G
- Published
- 2021
10. STATIN TREATMENT REDUCES THE RISK OF DEATH AMONG ELDERLY FRAIL PATIENTS. EVIDENCE FROM A LARGE POPULATION-BASED COHORT
- Author
-
Rea, F, Corrao, G, Mancia, G, Rea, F, Corrao, G, and Mancia, G
- Published
- 2021
11. Sex-related differences in chronic heart failure: a community-based study
- Author
-
Russo, G, Rea, F, Barbati, G, Cherubini, A, Stellato, K, Scagnetto, A, Iorio, A, Corrao, G, Di Lenarda, A, Russo, Giulia, Rea, Federico, Barbati, Giulia, Cherubini, Antonella, Stellato, Kira, Scagnetto, Arjuna, Iorio, Annamaria, Corrao, Giovanni, Di Lenarda, Andrea, Russo, G, Rea, F, Barbati, G, Cherubini, A, Stellato, K, Scagnetto, A, Iorio, A, Corrao, G, Di Lenarda, A, Russo, Giulia, Rea, Federico, Barbati, Giulia, Cherubini, Antonella, Stellato, Kira, Scagnetto, Arjuna, Iorio, Annamaria, Corrao, Giovanni, and Di Lenarda, Andrea
- Abstract
AIMS: To evaluate sex-related differences among real-life outpatients with chronic heart failure across the ejection fraction spectrum and to evaluate whether these differences might impact therapy and outcomes. METHODS: A total of 2528 heart failure patients were examined between 2009 and 2015 [mean age 76, 42% females; 59% with heart failure with preserved ejection fraction (HFpEF), 17% with heart failure with mid-range ejection fraction (HFmrEF) and 24% with heart failure with reduced ejection fraction (HFrEF)]. Females showed a higher prevalence of HFpEF than males. RESULTS: Females were older, less obese and with less ischaemic heart disease. They have renal failure and anaemia more frequently than males. There were no differences in terms of heart failure therapy in the HFrEF group, but a lower prescription rate of angiotensin-converting enzyme-I/AT1 blockers in HFmrEF and HFpEF and a higher prescription of mineralocorticoid receptor antagonists in the female group with HFpEF were observed. Crude rate mortality and composite outcome (death/heart failure progression) run similarly across sexes regardless of the ejection fraction categories. After adjustment, risk of mortality was significantly lower in females than males in the HFmrEF and HFpEF groups, whereas similar risk was confirmed across sexes in the HFrEF group. Considering prognostic risk factors, noncardiac comorbidities emerged in the HFpEF group. CONCLUSION: In a community-based heart failure cohort, females were differently distributed within heart failure phenotypes and they presented some different characteristics across ejection fraction categories. Although in an unadjusted model there was no significant difference for adverse outcomes, in an adjusted model females showed a lower risk of mortality in HFpEF and HFmrEF. Concerning sex-related prognostic risk factors, noncardiac comorbidities significantly affected adverse prognosis in females with HFpEF.
- Published
- 2021
12. Women discontinue antihypertensive drug therapy more than men. Evidence from an Italian population-based study
- Author
-
Rea, F, Mella, M, Monzio Compagnoni, M, Cantarutti, A, Merlino, L, Mancia, G, Corrao, G, Rea, Federico, Mella, Marta, Monzio Compagnoni, Matteo, Cantarutti, Anna, Merlino, Luca, Mancia, Giuseppe, Corrao, Giovanni, Rea, F, Mella, M, Monzio Compagnoni, M, Cantarutti, A, Merlino, L, Mancia, G, Corrao, G, Rea, Federico, Mella, Marta, Monzio Compagnoni, Matteo, Cantarutti, Anna, Merlino, Luca, Mancia, Giuseppe, and Corrao, Giovanni
- Abstract
Objective: Several factors affect adherence to antihypertensive drug treatment, but whether these factors include a sex difference is unclear. Aim of the study was to compare persistence with antihypertensive drug therapy between men and women in a large cohort of patients.Methods:The 60 526 residents of the Italian Lombardy Region aged 40-80 years newly treated with antihypertensive drugs during 2010 were identified and followed for 1 year after the first prescription. Discontinuation of treatment was defined as lack of prescription renewal for at least 90 days. Log-binomial regression models were fitted to estimate the risk ratio of treatment discontinuation in relation to sex. Other than for the whole population, analyses were stratified according to age, comorbidity status and the initial antihypertensive treatment strategy.Results:Thirty-seven percent of the patients discontinued the drug treatment during follow-up. Compared with women, men had a 10% lower risk of discontinuation of drug treatment (95% confidence interval: 8-12). Persistence on antihypertensive treatment was better in men than in women, this being the case in both younger (40-64 years) and older patients (65-80 years), in patients starting treatment with any major antihypertensive drug and in patients who had a low comorbidity status. There was no evidence that men and women had a different risk of treatment discontinuation when their comorbidity status was worse, or initial antihypertensive treatment was based on drug combinations.Conclusion:Our data show that in a real-life setting, men are more persistent to antihypertensive drug therapy than women.
- Published
- 2020
13. Noncandidal, fungal infections of the burn wound.
- Author
-
Burdge JJ, Rea F, and Ayers L
- Published
- 1988
- Full Text
- View/download PDF
14. WOMEN DISCONTINUE ANTIHYPERTENSIVE DRUG THERAPY MORE THAN MEN: EVIDENCE FROM AN ITALIAN POPULATION-BASED STUDY.
- Author
-
Rea, F., Mella, M., Monzio Compagnoni, M., Merlino, L., Corrao, G., and Mancia, G.
- Published
- 2019
- Full Text
- View/download PDF
15. IS ANTIHYPERTENSIVE TREATMENT PROTECTIVE IN ELDERLY FRAIL PATIENTS? EVIDENCE FROM AN ITALIAN REAL-WORLD POPULATION.
- Author
-
Rea, F., Occhino, G., Cantarutti, A., Merlino, L., Ungar, A., Corrao, G., and Mancia, G.
- Published
- 2019
- Full Text
- View/download PDF
16. A celiac toddler with Graves' disease.
- Author
-
Rea, F., Pluvio, R., Sergio, A., Di Domenico, M.R., and Polito, C.
- Published
- 2000
- Full Text
- View/download PDF
17. Evaluating sources of bias in observational studies
- Author
-
Giuseppe Mancia, Federico Rea, Giovanni Corrao, Corrao, G, Rea, F, and Mancia, G
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Physiology ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Computational biology ,Observational studie ,Bia ,Internal Medicine ,Medicine ,Observational study ,Cardiology and Cardiovascular Medicine ,business ,Covid-19 - Published
- 2021
18. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).
- Author
-
Amil-Dias J, Oliva S, Papadopoulou A, Thomson M, Gutiérrez-Junquera C, Kalach N, Orel R, Auth MK, Nijenhuis-Hendriks D, Strisciuglio C, Bauraind O, Chong S, Ortega GD, Férnandez SF, Furman M, Garcia-Puig R, Gottrand F, Homan M, Huysentruyt K, Kostovski A, Otte S, Rea F, Roma E, Romano C, Tzivinikos C, Urbonas V, Velde SV, Zangen T, and Zevit N
- Subjects
- Humans, Child, Gastroenterology standards, Gastroenterology methods, Europe, Societies, Medical, Eosinophilic Esophagitis diagnosis, Eosinophilic Esophagitis therapy
- Abstract
Introduction: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus characterized by symptoms of esophageal dysfunction and histologically by predominantly eosinophilic infiltration of the squamous epithelium. European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) published a guideline in 2014; however, the rapid evolution of knowledge about pathophysiology, diagnostic criteria, and therapeutic options have made an update necessary., Methods: A consensus group of pediatric gastroenterologists from the ESPGHAN Working Group on Eosinophilic Gastrointestinal Diseases (ESPGHAN EGID WG) reviewed the recent literature and proposed statements and recommendations on 28 relevant questions about EoE. A comprehensive electronic literature search was performed in MEDLINE, EMBASE, and Cochrane databases from 2014 to 2022. The Grading of Recommendations Assessment, Development and Evaluation system was used to assess the quality of evidence and formulate recommendations., Results: A total of 52 statements based on the available evidence and 44 consensus-based recommendations are available. A revision of the diagnostic protocol, options for initial drug treatment, and the new concept of simplified empiric elimination diets are now available. Biologics are becoming a part of the potential armamentarium for refractory EoE, and systemic steroids may be considered as the initial treatment for esophageal strictures before esophageal dilation. The importance and assessment of quality of life and a planned transition to adult medical care are new areas addressed in this guideline., Conclusion: Research in recent years has led to a better understanding of childhood EoE. This guideline incorporates the new findings and provides a practical guide for clinicians treating children diagnosed with EoE., (© 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2024
- Full Text
- View/download PDF
19. Mediastinal Germ-cell Tumors Relapse in a Male With Klinefelter Syndrome. Is Longer Surveillance Needed?
- Author
-
Stefanachi F, Affinita MC, Fichera G, Tagarelli A, De Corti F, Rea F, and Bisogno G
- Subjects
- Child, Humans, Male, Neoplasm Recurrence, Local, Chronic Disease, Klinefelter Syndrome complications, Klinefelter Syndrome diagnosis, Mediastinal Neoplasms complications, Mediastinal Neoplasms diagnosis, Mediastinal Neoplasms pathology, Neoplasms, Germ Cell and Embryonal complications, Neoplasms, Germ Cell and Embryonal diagnosis
- Abstract
Germ cell tumors (GCTs) are a heterogeneous group of pediatric cancers. In up to one-third of male patients, a primary mediastinal location is associated with the presence of Klinefelter syndrome (KS). We describe a case of mediastinal GCT in a patient, with unacknowledged KS, that presented a relapse 7 years from diagnosis, that is, 2 years after the end of the follow-up program usually recommended for patients with GCT. There are no recommendations for screening for KS in patients with mediastinal GCT and there are no specific guidelines for surveillance of GCT in KS patients. Our experience suggests that KS should be suspected in patients with mediastinal GCT, and a longer follow-up plan should be implemented when GCT occurs in patients with KS., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
20. Diaphragm Dysfunction Predicts Weaning Outcome after Bilateral Lung Transplant.
- Author
-
Boscolo A, Sella N, Pettenuzzo T, Pistollato E, Calabrese F, Gregori D, Cammarota G, Dres M, Rea F, and Navalesi P
- Subjects
- Adult, Humans, Diaphragm diagnostic imaging, Respiration, Artificial, Respiration, Ventilator Weaning, Lung Transplantation
- Abstract
Background: Diaphragm dysfunction and its effects on outcomes of ventilator weaning have been evaluated in mixed critical care populations using diaphragm thickening fraction (the ratio of the difference between ultrasound diaphragm thickness at end-inspiration and end-expiration to diaphragm thickness at end-expiration) or neuroventilatory efficiency (the ratio of tidal volume and peak electrical activity of the diaphragm). Such data are not available in bilateral-lung transplant recipients. The authors hypothesized that (1) diaphragm dysfunction, as defined by a diaphragm thickening fraction less than 29%, is more likely to occur in difficult weaning; (2) diaphragm thickening fraction and neuroventilatory efficiency predict weaning outcome; and (3) duration of mechanical ventilation before the first spontaneous breathing trial is associated with diaphragm dysfunction., Methods: Adult bilateral-lung transplant patients admitted to the intensive care unit were screened at the time of the first spontaneous breathing trial (pressure-support of 5 cm H2O and 0 positive end-expiratory pressure). At the fifth minute, diaphragm thickening fraction and neuroventilatory efficiency were measured during three respiratory cycles. Weaning was classified as simple, difficult, or prolonged (successful extubation at the first spontaneous breathing trial, within three or after three spontaneous breathing trials, respectively)., Results: Forty-four subjects were enrolled. Diaphragm dysfunction occurred in 14 subjects (32%), all of whom had difficult weaning (78% of the subgroup of 18 patients experiencing difficult weaning). Both diaphragm thickening fraction (24 [20 to 29] vs. 39 [35 to 45]%) and neuroventilatory efficiency (34 [26 to 45] vs. 55 [43 to 62] ml/µV) were lower in difficult weaning (both P < 0.001). The areas under the receiver operator curve predicting difficult weaning were 0.88 (95% CI, 0.73 to 0.99) for diaphragm thickening fraction and 0.85 (95% CI, 0.71 to 0.95) for neuroventilatory efficiency. The duration of ventilation demonstrated a linear inverse correlation with both diaphragm thickening fraction and neuroventilatory efficiency., Conclusions: Diaphragm dysfunction is common after bilateral-lung transplantation and associated with difficult weaning. In such patients, average values for diaphragm thickening fraction and neuroventilatory efficiency were reduced compared to patients with simple weaning. Both parameters showed similar accuracy for predicting success of ventilator weaning, demonstrating an inverse relationship with duration of ventilation., (Copyright © 2023 American Society of Anesthesiologists. All Rights Reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Oral Viscous Budesonide in Children With Eosinophilic Esophagitis After Repaired Esophageal Atresia: A Clinical Trial.
- Author
-
Tambucci R, Roversi M, Rea F, Malamisura M, Angelino G, Biondi I, Simeoli R, Goffredo BM, Francalanci P, Simonetti A, Livadiotti S, Corsetti T, Dall'Oglio L, Rossi P, Pontrelli G, and De Angelis P
- Subjects
- Child, Humans, Infant, Treatment Outcome, Budesonide therapeutic use, Glucocorticoids therapeutic use, Eosinophilic Esophagitis pathology, Esophageal Atresia drug therapy, Esophageal Atresia surgery, Esophageal Atresia complications
- Abstract
Objectives: A high prevalence of eosinophilic esophagitis (EoE) has been reported in children with repaired esophageal atresia (EA). Topical steroids proved to be an effective and safe therapy in EoE, although not approved in pediatrics. We report the results of the first clinical trial of oral viscous budesonide (OVB) performed in children with EoE after repaired esophageal atresia (EoE-EA)., Methods: This open-label, single-arm, phase 2 clinical trial with randomized pharmacokinetic sampling, was conducted at the Bambino Gesù Children's Hospital between September 2019 and June 2021. EoE-EA patients received an age-banded dose of OVB twice daily for 12 weeks and were endoscopically evaluated. The primary endpoint was the rate of patients achieving histological remission. Secondary endpoints included clinical and endoscopic benefit after treatment, and safety assessments., Results: Eight consecutive EA-EoE patients were enrolled (median age 9.1 years, interquartile range 5.5). Of these, 5 received 0.8 mg and 3 received 1.0 mg twice daily of OVB. Histological remission was obtained in all but 1 patient (87.5%). The clinical score showed significant improvement at the end of treatment in all patients. No endoscopic features of EoE were found after treatment. No treatment-emergent adverse event occurred., Conclusion: OVB is an effective, safe, and well-tolerated formulation of budesonide for use in pediatric patients with EoE-EA., Competing Interests: The authors report no conflicts of interest., (Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2023
- Full Text
- View/download PDF
22. Characterization of Eosinophilic Esophagitis From the European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHAN.
- Author
-
Oliva S, Dias JA, Rea F, Malamisura M, Espinheira MC, Papadopoulou A, Koutri E, Rossetti D, Orel R, Homan M, Bauraind O, Auth MK, Junquera CG, Vande Velde S, Kori M, Huysentruyt K, Urbonas V, Roma E, Fernández SF, Domínguez-Ortega G, Zifman E, Kafritsa P, Miele E, and Zevit N
- Subjects
- Adolescent, Child, Child, Preschool, Delayed Diagnosis, Endoscopy, Gastrointestinal, Enteritis, Eosinophilia, Female, Gastritis, Humans, Male, Proton Pump Inhibitors therapeutic use, Registries, Deglutition Disorders drug therapy, Deglutition Disorders etiology, Eosinophilic Esophagitis complications, Eosinophilic Esophagitis diagnosis, Eosinophilic Esophagitis epidemiology, Food Hypersensitivity
- Abstract
Objectives: Few pediatric data on phenotypic aspects of eosinophilic esophagitis (EoE) are available. The pEEr registry was developed to prospectively characterize children with EoE from Europe and Israel., Methods: pEEr is an ongoing prospective registry enrolling children with esophageal eosinophilia (≥15 eos/HPF). Anonymized data were collected from 19 pediatric centers. Data regarding demographics, clinical manifestations, endoscopy, histology, and therapies were collected., Results: A total of 582 subjects (61% male) were analyzed. The median age at diagnosis was 10.5 years [interquartile range (IQR): 5.7-17.7], whereas the age at symptom onset was 9.2 years (IQR: 4.3-16.4), resulting in a median diagnostic delay of 1.2 years (IQR: 0.7-2.3). The diagnostic delay was longer below age <6 years. Shorter diagnostic delays were associated with the presence of food allergy or a family history for EoE. Symptoms varied by age with dysphagia and food impaction more common in adolescents, while vomiting and failure to thrive more common in younger children ( P < 0.001). Among endoscopic findings, esophageal rings were more common in adolescents, whereas exudates were more frequent in younger children( P < 0.001). Patients who responded to proton pump inhibitors (PPIs) were more likely to be older, males, and less often presented severe endoscopic findings. Patients unresponsive to PPIs received topical steroids (40%), elimination diet (41%), or a combined therapy (19%)., Conclusions: EoE findings vary according to age in pediatric EoE. Young children are commonly characterized by non-specific symptoms, atopic dermatitis, food allergy, and inflammatory endoscopic lesions. Adolescents usually have dysphagia or food impaction, fibrostenotic lesions, and a better PPI response., Competing Interests: Noam Zevit: consultation fees – Dr Falk Pharma, Adare Pharmaceuticals; speaker fees – Rafa inc and Sanofi. Salvatore Oliva: consultation fees – Medtronic, Ocean Farma; speaker fees – Medtronic. Marcus Karl-Heinz Auth – consultation fees: Dr Falk Pharma; educational grants: Nutricia, Mead Johnson. Alexandra Papadopoulou: research grants from Abbvie, United Pharmaceuticals, Dr Falk Pharma GmbH, Takeda, AstraZeneca; speaker or consultation fees from Adare Pharmaceuticals, Dr Falk Pharma GmbH, Specialty Therapeutics, Uni-Pharma Pharmaceuticals Laboratories S.A., Cross Pharmaceuticals, Petsiavas, Nestle, Touch Independent Medical Education, and Sanofi-Aventis. The remaining authors report no conflicts of interest., (Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2022
- Full Text
- View/download PDF
23. Systematic Review and Meta-analysis of Histological Gastric Biopsy Aspects According to the Updated Sydney System in Children.
- Author
-
Kalach N, Misak Z, Bontems P, Kori M, Homan M, Cabral J, Casswall T, Chong S, Cilleruelo ML, Faraci S, Megraud F, Papadopoulou A, Pehlivanoglu E, Raymond J, Rea F, Maria R, Roma E, Tavares M, Ugras M, Urbonas V, Urruzuno P, Gosset P, Creusy C, Delebarre M, and Verdun S
- Subjects
- Biopsy, Child, Gastric Mucosa, Gastroscopy, Humans, Metaplasia pathology, Gastritis complications, Gastritis diagnosis, Gastritis epidemiology, Helicobacter Infections complications, Helicobacter Infections diagnosis, Helicobacter Infections epidemiology, Helicobacter pylori
- Abstract
Objectives: A descriptive and comparative study of gastric histological aspects according to the updated Sydney classification (USC), obtained from Helicobacter pylori-positive versus H pylori-negative children referred for upper gastrointestinal endoscopy., Methods: The Prisma method was used to perform a systematic review and meta-analysis. Selection criteria were based on following key words USC, H pylori, children, endoscopy, or biopsy. Publication biases were assessed according to the Newcastle-Ottawa Scale, and a meta-regression analysis was done. The study was registered on the PROSPERO platform., Results: Between 1994 and 2017, 1238 references were found; 97 studies were retained for the systematic review with a total number of 25,867 children; 75 studies were selected for the meta-analysis concerning 5990 H pylori-infected and 17,782 uninfected children.H pylori-positive versus H pylori-negative children, according to the USC, showed significantly higher relative risk for gastric antral and corpus chronic inflammation, presence of neutrophils, and of lymphoid follicles, and gastric mucosa atrophy, whereas, intestinal metaplasia showed a significantly higher RR only in antral biopsies. The meta-regression analysis showed that H pylori-positive versus H pylori-negative children had significantly higher risk only for corpus activity according to age, recurrent abdominal pain, and geographical area of low H pylori prevalence., Conclusions: H pylori infection in children was associated with higher relative risk for gastric antral and corpus chronic inflammation, presence of neutrophils, lymphoid follicles, and rare gastric mucosa atrophy, whereas, rare intestinal metaplasia was only significantly higher in the antral area., (Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2022
- Full Text
- View/download PDF
24. Break the Rule of Three: Critical Thoughts From a Tertiary Care Experience With Bougie Dilators.
- Author
-
Tambucci R, Malamisura M, Napoli M, Rea F, Faraci S, Romeo EF, Angelino G, Caldaro T, Guerra L, Contini ACI, Federici di Abriola G, Dall'Oglio L, De Angelis P, and Torroni F
- Subjects
- Child, Constriction, Pathologic, Dilatation, Humans, Tertiary Healthcare, Esophageal Stenosis
- Published
- 2021
- Full Text
- View/download PDF
25. Sex-related differences in chronic heart failure: a community-based study.
- Author
-
Russo G, Rea F, Barbati G, Cherubini A, Stellato K, Scagnetto A, Iorio A, Corrao G, and Di Lenarda A
- Subjects
- Age Factors, Aged, Aged, 80 and over, Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Chronic Disease, Comorbidity, Female, Health Status Disparities, Heart Failure diagnostic imaging, Heart Failure drug therapy, Heart Failure mortality, Humans, Longitudinal Studies, Male, Mineralocorticoid Receptor Antagonists therapeutic use, Prevalence, Prospective Studies, Registries, Risk Assessment, Risk Factors, Sex Factors, Treatment Outcome, Heart Failure physiopathology, Stroke Volume drug effects, Ventricular Function, Left drug effects
- Abstract
Aims: To evaluate sex-related differences among real-life outpatients with chronic heart failure across the ejection fraction spectrum and to evaluate whether these differences might impact therapy and outcomes., Methods: A total of 2528 heart failure patients were examined between 2009 and 2015 [mean age 76, 42% females; 59% with heart failure with preserved ejection fraction (HFpEF), 17% with heart failure with mid-range ejection fraction (HFmrEF) and 24% with heart failure with reduced ejection fraction (HFrEF)]. Females showed a higher prevalence of HFpEF than males., Results: Females were older, less obese and with less ischaemic heart disease. They have renal failure and anaemia more frequently than males. There were no differences in terms of heart failure therapy in the HFrEF group, but a lower prescription rate of angiotensin-converting enzyme-I/AT1 blockers in HFmrEF and HFpEF and a higher prescription of mineralocorticoid receptor antagonists in the female group with HFpEF were observed. Crude rate mortality and composite outcome (death/heart failure progression) run similarly across sexes regardless of the ejection fraction categories. After adjustment, risk of mortality was significantly lower in females than males in the HFmrEF and HFpEF groups, whereas similar risk was confirmed across sexes in the HFrEF group. Considering prognostic risk factors, noncardiac comorbidities emerged in the HFpEF group., Conclusion: In a community-based heart failure cohort, females were differently distributed within heart failure phenotypes and they presented some different characteristics across ejection fraction categories. Although in an unadjusted model there was no significant difference for adverse outcomes, in an adjusted model females showed a lower risk of mortality in HFpEF and HFmrEF. Concerning sex-related prognostic risk factors, noncardiac comorbidities significantly affected adverse prognosis in females with HFpEF.
- Published
- 2021
- Full Text
- View/download PDF
26. Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016.
- Author
-
Kori M, Le Thi TG, Werkstetter K, Sustmann A, Bontems P, Lopes AI, Oleastro M, Iwanczak B, Kalach N, Misak Z, Cabral J, Homan M, Cilleruelo Pascual ML, Pehlivanoglu E, Casswall T, Urruzuno P, Martinez Gomez MJ, Papadopoulou A, Roma E, Dolinsek J, Rogalidou M, Urbonas V, Chong S, Kindermann A, Miele E, Rea F, Cseh Á, and Koletzko S
- Subjects
- Amoxicillin therapeutic use, Anti-Bacterial Agents therapeutic use, Child, Clarithromycin therapeutic use, Drug Therapy, Combination, Europe, Female, Humans, Israel epidemiology, Male, Metronidazole therapeutic use, Registries, Turkey, Helicobacter Infections drug therapy, Helicobacter Infections epidemiology, Helicobacter pylori
- Abstract
Objectives: The aim of the study was to assess clinical presentation, endoscopic findings, antibiotic susceptibility and treatment success of Helicobacter pylori (H. pylori) infected pediatric patients., Methods: Between 2013 and 2016, 23 pediatric hospitals from 17 countries prospectively submitted data on consecutive H. pylori-infected (culture positive) patients to the EuroPedHP-Registry., Results: Of 1333 patients recruited (55.1% girls, median age 12.6 years), 1168 (87.6%) were therapy naïve (group A) and 165 (12.4%) had failed treatment (group B). Patients resided in North/Western (29.6%), Southern (34.1%) and Eastern Europe (23.0%), or Israel/Turkey (13.4%). Main indications for endoscopy were abdominal pain or dyspepsia (81.2%, 1078/1328). Antral nodularity was reported in 77.8% (1031/1326) of patients, gastric or duodenal ulcers and erosions in 5.1% and 12.8%, respectively. Primary resistance to clarithromycin (CLA) and metronidazole (MET) occurred in 25% and 21%, respectively, and increased after failed therapy. Bacterial strains were fully susceptible in 60.5% of group A, but in only 27.4% of group B. Primary CLA resistance was higher in Southern and Eastern Europe (adjusted odds ratio [ORadj] = 3.44, 95% confidence interval [CI] 2.22-5.32, P < 0.001 and 2.62, 95% CI: 1.63-4.22, P < 0.001, respectively) compared with Northern/Western Europe. Children born outside Europe showed higher primary MET resistance (ORadj = 3.81, 95% CI: 2.25-6.45, P < 0.001). Treatment success in group A reached only 79.8% (568/712) with 7 to 14 days triple therapy tailored to antibiotic susceptibility., Conclusions: Peptic ulcers are rare in dyspeptic H. pylori-infected children. Primary resistance to CLA and MET is markedly dependent on geographical regions of birth and residence. The ongoing survey will show whether implementation of the updated ESPGHAN/NASPGHAN guidelines will improve the eradication success.
- Published
- 2020
- Full Text
- View/download PDF
27. Pediatric Eosinophilic Esophagitis: Results of the European Retrospective Pediatric Eosinophilic Esophagitis Registry (RetroPEER).
- Author
-
Hoofien A, Dias JA, Malamisura M, Rea F, Chong S, Oudshoorn J, Nijenhuis-Hendriks D, Otte S, Papadopoulou A, Romano C, Gottrand F, Miravet VV, Orel R, Oliva S, Junquera CG, Załęski A, Urbonas V, Garcia-Puig R, Gomez MJM, Dominguez-Ortega G, Auth MK, Kori M, Ben Tov A, Kalach N, Velde SV, Furman M, Miele E, Marderfeld L, Roma E, and Zevit N
- Subjects
- Adolescent, Child, Child, Preschool, Eosinophilic Esophagitis diagnosis, Eosinophilic Esophagitis drug therapy, Europe epidemiology, Female, Humans, Male, Retrospective Studies, Eosinophilic Esophagitis epidemiology, Registries
- Abstract
Objectives: Recommendations for diagnosing and treating eosinophilic esophagitis (EoE) are evolving; however, information on real world clinical practice is lacking. To assess the practices of pediatric gastroenterologists diagnosing and treating EoE and to identify the triggering allergens in European children., Methods: Retrospective anonymized data were collected from 26 European pediatric gastroenterology centers in 13 countries. Inclusion criteria were: Patients diagnosis with EoE, completed investigations prescribed by the treating physician, and were on stable medical or dietary interventions., Results: In total, 410 patients diagnosed between December 1999 and June 2016 were analyzed, 76.3% boys. The time from symptoms to diagnosis was 12 ± 33.5 months and age at diagnosis was 8.9 ± 4.75 years. The most frequent indications for endoscopy were: dysphagia (38%), gastroesophageal reflux (31.2%), bolus impaction (24.4%), and failure to thrive (10.5%). Approximately 70.3% had failed proton pump inhibitor treatment. The foods found to be causative of EoE by elimination and rechallenge were milk (42%), egg (21.5%), wheat/gluten (10.9%), and peanut (9.9%). Elimination diets were used exclusively in 154 of 410 (37.5%), topical steroids without elimination diets in 52 of 410 (12.6%), both diet and steroids in 183 of 410 (44.6%), systemic steroids in 22 of 410 (5.3%), and esophageal dilation in 7 of 410 (1.7%). Patient refusal, shortage of endoscopy time, and reluctance to perform multiple endoscopies per patient were noted as factors justifying deviation from guidelines., Conclusions: In this "real world" pediatric European cohort, milk and egg were the most common allergens triggering EoE. Although high-dose proton pump inhibitor trials have increased, attempted PPI treatment is not universal.
- Published
- 2019
- Full Text
- View/download PDF
28. Two-Drug Combinations as First-Step Antihypertensive Treatment.
- Author
-
Mancia G, Rea F, Corrao G, and Grassi G
- Subjects
- Antihypertensive Agents adverse effects, Drug Combinations, Healthcare Disparities, Humans, Hypertension diagnosis, Hypertension epidemiology, Hypertension physiopathology, Medication Adherence, Risk Factors, Treatment Outcome, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Hypertension drug therapy
- Abstract
Blood pressure (BP) control in patients with hypertension is variable worldwide, and in general, it results largely unsatisfactory. Factors responsible for this phenomenon include insufficient national cardiovascular healthcare policies for prevention, poor patient compliance with prescribed treatment schedules, and the reluctance of physicians to modify treatment strategies when BP is still elevated, that is, the so-called therapeutic inertia. A further important factor favoring poor BP control is the limited use of combination drug treatment, despite evidence of its superior ability to control BP in patients with difficult-to-treat hypertension. In addition, combination treatment allows to achieve BP control more easily (and more quickly) as compared with monotherapy. This article, after briefly examining the main features of BP control, will review the importance in the treatment of hypertension of the drug combination strategy, based on the recommendations of the 2018 European Society of Cardiology/European Society of Hypertension guidelines. Empahsis will be given to the drug combination treatment as first step of the antihypertensive therapeutic intervention. The potential drawbacks and barriers to combination drug treatment as initial therapeutic strategy will also be briefly discussed.
- Published
- 2019
- Full Text
- View/download PDF
29. Feasibility and Utility of Chest-X ray on Portable Normothermic Perfusion System.
- Author
-
Schiavon M, Di Gregorio G, Marulli G, Rebusso A, Battistel M, Lunardi F, Miotto D, Calabrese F, and Rea F
- Subjects
- Feasibility Studies, Female, Humans, Lung Transplantation methods, Middle Aged, Perfusion methods, Predictive Value of Tests, Pulmonary Fibrosis diagnosis, Donor Selection, Lung diagnostic imaging, Lung Transplantation instrumentation, Perfusion instrumentation, Pulmonary Fibrosis surgery, Radiography instrumentation, Tissue Donors
- Published
- 2016
- Full Text
- View/download PDF
30. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.
- Author
-
Rea F, Potena L, Yonan N, Wagner F, and Calabrese F
- Subjects
- Antiviral Agents administration & dosage, Cytomegalovirus drug effects, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections immunology, Host-Pathogen Interactions, Humans, Immunization, Passive, Immunocompromised Host, Immunoglobulins adverse effects, Immunoglobulins, Intravenous, Immunosuppressive Agents adverse effects, Opportunistic Infections diagnosis, Opportunistic Infections epidemiology, Opportunistic Infections immunology, Registries, Time Factors, Treatment Outcome, Virus Activation, Cytomegalovirus immunology, Cytomegalovirus Infections prevention & control, Heart Transplantation adverse effects, Immunoglobulins administration & dosage, Lung Transplantation adverse effects, Opportunistic Infections prevention & control
- Abstract
Cytomegalovirus (CMV) infection negatively influences both short- and long-term outcomes after cardiothoracic transplantation. In heart transplantation, registry analyses have shown that CMV immunoglobulin (CMVIG) with or without virostatic prophylaxis is associated with a significant reduction in mortality and graft loss versus no prophylaxis, particularly in high-risk donor (D)+/recipient (R)- transplants. Randomized comparative trials are lacking but retrospective data suggest that addition of CMVIG to antiviral prophylaxis may reduce rates of CMV-related events after heart transplantation, including the incidence of acute rejection or chronic allograft vasculopathy. However, available data consistently indicate that when CMVIG is used, it should be administered with concomitant antiviral therapy, and that evidence concerning preemptive management with CMVIG is limited, but promising. In lung transplantation, CMVIG should again only be used with concomitant antiviral therapy. Retrospective studies have shown convincing evidence that addition of CMVIG to antiviral prophylaxis lowers CMV endpoints and mortality. The current balance of evidence suggests that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled trial is awaited. Overall, the relatively limited current data set suggests that prophylaxis with CMVIG in combination with antiviral therapy appears effective in D+/R- heart transplant patients, whereas in lung transplantation, addition of CMVIG in recipients of a CMV-positive graft may offer an advantage in terms of CMV infection and disease.
- Published
- 2016
- Full Text
- View/download PDF
31. Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis.
- Author
-
Calabrese F, Lunardi F, Balestro E, Marulli G, Perissinotto E, Loy M, Nannini N, Valente M, Saetta M, Agostini C, and Rea F
- Subjects
- Adult, Aged, Carcinoma in Situ complications, Carcinoma in Situ diagnosis, Cell Proliferation, Female, Humans, Idiopathic Pulmonary Fibrosis complications, Idiopathic Pulmonary Fibrosis diagnosis, Ki-67 Antigen metabolism, Lung Neoplasms complications, Lung Neoplasms diagnosis, Lung Transplantation, Male, Middle Aged, Prognosis, Protein Isoforms, Respiratory Mucosa pathology, Transforming Growth Factor beta metabolism, Antigens, Neoplasm metabolism, Carcinoma in Situ metabolism, Idiopathic Pulmonary Fibrosis metabolism, Lung Neoplasms metabolism, Respiratory Mucosa metabolism, Serpins metabolism
- Abstract
Aims: The aim of the study was to evaluate the role of Serpin B3/B4 in advanced idiopathic pulmonary fibrosis (IPF) patients, mainly focusing on epithelial proliferation., Methods: Lungs from 48 IPF patients (including cases with cancer or high-grade epithelial dysplasia) were studied and compared with other diffuse parenchymal diseases and normal lungs. Immunohistochemistry for Serpin B3/B4 and Ki-67 was quantified in all cases, distinguishing stained metaplastic cells. In IPF patients correlations between Serpin expression and several clinicopathological data, including fibrotic remodelling [fibrosis extension and transforming growth factor β expression (TGF-β)] were performed. Molecular analysis was used for Serpin isoform characterisation., Results: In IPF patients Serpin B3/B4 and Ki-67 were significantly overexpressed in many metaplastic cells (mainly squamous type) compared to control cases. Higher Serpin B3/B4 was found in older patients and cases with more impaired respiratory function. Serpin B3/B4 expression was related to both TGF-β and Ki-67 and was higher in patients with cancer/high-grade dysplasia. Serpin B3 was expressed in all cases, whereas Serpin B4 was expressed only in IPF., Conclusions: Serpin B3/B4, particularly Serpin B4, appears to play an important role in aberrant epithelial proliferation. Evaluation of Serpin B3/B4 could have prognostic value in predicting disease progression, especially in patients with increased susceptibility to lung cancer., ((C) 2012 Royal College of Pathologists of Australasia.)
- Published
- 2012
- Full Text
- View/download PDF
32. Anterior gradient 2 overexpression in lung adenocarcinoma.
- Author
-
Pizzi M, Fassan M, Balistreri M, Galligioni A, Rea F, and Rugge M
- Subjects
- Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Female, Humans, Male, Mucoproteins, Oncogene Proteins, RNA, Messenger biosynthesis, RNA, Neoplasm biosynthesis, Real-Time Polymerase Chain Reaction methods, Retrospective Studies, Adenocarcinoma metabolism, Adenocarcinoma pathology, Biomarkers, Tumor biosynthesis, Gene Expression Regulation, Neoplastic, Lung Neoplasms metabolism, Lung Neoplasms pathology, Proteins metabolism
- Abstract
The histologic subtyping of the 2 major histotypes of nonsmall-cell lung cancer, that is, adenocarcinoma (AdC) and squamous cell carcinoma (SCC), is crucial to therapeutic decision making, but making this distinction can be a challenge. Querying the Oncomine database pinpointed anterior gradient 2 (AGR2) as being upregulated in lung AdC. On applying both quantitative real-time polymerase chain reaction and immunohistochemistry, this study tested the reliability of AGR2 status as a histotype-specific marker of lung AdC. AGR2 immunohistochemistry expression was semiquantitatively assessed in 120 cases of lung cancer (60 AdCs, 60 SCCs); 35 additional tissue samples from non-neoplastic lungs were considered as normal controls. To further support our findings, the expression of AGR2 mRNA was tested by quantitative real-time polymerase chain reaction in 30 of the considered cases (10 AdCs, 10 SCCs, and 10 normal lungs). AGR2 was consistently expressed in normal bronchial/bronchiolar columnar cells. Cases of AdC always expressed the protein (staining moderately in 30% and strongly in 70%), whereas none of the SCC cases strongly expressed AGR2 (staining was negative in 55%, weak in 33%, and moderate in 12%). AGR2 mRNA was significantly overexpressed in AdCs by comparison with SCCs (P=0.003) or normal lung tissue (P=0.002). AGR2 is upregulated in lung AdC (by comparison with either SCC or normal bronchial/bronchiolar columnar cells). AGR2 protein expression may support the histologic subtyping of nonsmall-cell lung cancer and be of clinical value in differentiating lung AdC from SCC.
- Published
- 2012
- Full Text
- View/download PDF
33. Autoimmune thyroid disease and celiac disease in children.
- Author
-
Ansaldi N, Palmas T, Corrias A, Barbato M, D'Altiglia MR, Campanozzi A, Baldassarre M, Rea F, Pluvio R, Bonamico M, Lazzari R, and Corrao G
- Subjects
- Adolescent, Autoimmune Diseases diagnostic imaging, Autoimmune Diseases physiopathology, Celiac Disease diagnostic imaging, Celiac Disease physiopathology, Child, Child, Preschool, Comorbidity, Female, Humans, Infant, Male, Prevalence, Thyroid Diseases diagnostic imaging, Thyroid Diseases physiopathology, Ultrasonography, Autoimmune Diseases epidemiology, Celiac Disease epidemiology, Thyroid Diseases epidemiology
- Abstract
Background: Celiac disease (CD) may be associated with other immunologic disorders in adults and children. Previous studies linking CD and autoimmune thyroid disease in children have included very few patients with limited biochemical and immunologic screening tests. The aim of this multicenter study was to establish the prevalence of autoimmune thyroid involvement in a large series of pediatric patients with CD., Methods: Five hundred seventy-three consecutive pediatric patients were enrolled from clinics in Torino, Bologna, Foggia, Rome (two clinics), Naples, and Bari. Three hundred forty-three patients with CD were studied, 230 girls and 113 boys (median age, 8.5 years). Two hundred fifty-six of the patients with CD (median age, 9 years) had been following a gluten-free diet for 3 months to 16 years; 87 patients were untreated (median age, 6.2 years). The diagnosis of CD was made using the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria. A control group of 230 subjects (median age, 8.3 years) was enrolled. Serum free triiodothyronine, free thyroxine, and thyroid-stimulating hormone (TSH), antithyroperoxidase, antithyroglobulin, anti-TSH receptor antibodies, and thyroid echographic pattern were considered., Results: Autoimmune thyroid disease was found in 90 of 343 (26.2%) patients with CD (62 on a gluten-free diet) and in 20 (10%) of the control subjects (P = 0.001). Fifty-four (15.7%) patients with CD and autoimmune markers had normal thyroid function (euthyroidism) as did 12 (6.0%) of the control subjects; hypothyroidism was observed in 28 (8.1%) patients with CD and in 7 (3.5%) of the control subjects. Hyperthyroidism was diagnosed in four patients with CD and in none of the control subjects with autoimmune markers. An abnormal echographic pattern was seen in 37 patients with CD (16.8%) and only in 1 (1.6%) of the control subjects (P = 0.002)., Conclusions: The high frequency of autoimmune thyroid disease found among patients with CD, even those on a gluten-free diet, may justify a thyroid status assessment at diagnosis and at follow-up evaluation of children with CD.
- Published
- 2003
- Full Text
- View/download PDF
34. Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation.
- Author
-
Calabrese F, Giacometti C, Rea F, Loy M, Sartori F, Di Vittorio G, Abudureheman A, Thiene G, and Valente M
- Subjects
- Adult, Hemosiderosis pathology, Humans, Lung pathology, Lung Diseases pathology, Male, Recurrence, Hemosiderosis surgery, Lung Diseases surgery, Lung Transplantation
- Abstract
Background: Idiopathic pulmonary hemosiderosis (IPH) is a rare disease of unknown etiology characterized by hemoptysis, diffuse pulmonary infiltration, and anemia. Diagnosis requires a detailed clinical history and transbronchial lung biopsy (TLB)., Methods and Results: A 19-year-old man developed progressive dyspnea, hemoptysis, and anemia. The chest x-rays showed bilateral opacities. IPH was diagnosed on the basis of clinical findings and TLB. The patient was treated with corticosteroidal therapy. His respiratory function worsened, and he underwent lung transplantation in 1997. The pathological examination on native lungs confirmed the previous histologic diagnosis. In 2000, the patient again developed hemoptysis, fever, and hypoxemia. A recurrence of the disease was established by TLB., Conclusions: This is the first report of recurring IPH. The possibility of recurrent IPH raises the question whether these patients should be disqualified from lung transplantation. This question is unanswerable because incidence of recurrence, time course, and impact on the graft function are presently unknown and unpredictable.
- Published
- 2002
- Full Text
- View/download PDF
35. Ultrarapid high-dose course of prophylactic cranial irradiation in small-cell lung cancer: evaluation of late neurologic morbidity in 16 long-term survivors.
- Author
-
Tomio L, Romano M, Zanchin G, Carollo C, Amista P, Loreggian L, Saladini G, Berti F, Pignataro M, Paccagnella A, Favaretto A, Rea F, and Calzavara F
- Subjects
- Adult, Aged, Brain diagnostic imaging, Brain radiation effects, Brain Neoplasms secondary, Combined Modality Therapy, Electroencephalography, Female, Humans, Male, Middle Aged, Radiotherapy Dosage, Survival Analysis, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed, Brain Neoplasms prevention & control, Carcinoma, Small Cell secondary, Carcinoma, Small Cell therapy, Cranial Irradiation, Lung Neoplasms pathology, Lung Neoplasms therapy
- Abstract
Despite the reduction in the incidence of brain metastases following prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC), the use of this modality is still controversial due to the lack of improvement in survival and the appearance of neurotoxicity in long-term survivors. Moreover, the optimum dose, fraction size, and timing are not known. From 1980 to 1988, 70 patients with limited stage SCLC underwent PCI after or during multimodality treatment of their primary tumor. Most of these patients (75.7%) received an unconventional ultrarapid high-dose course of 17 Gy in two fractions over 3 days. Long-term (range 60-138 months) survivors (n = 16) were invited to have a complete neurological evaluation including computed cranial tomography (CCT), 99mTc-HMPAO single photon emission computerized tomography (SPECT) scan, electroencephalography (EEG), magnetic resonance imaging (MRI), and neuropsychometry. Delayed neurologic complications or psychometric impairment was observed in 46% of patients. One or more abnormalities were detected by CCT in all patients, and the presence of neurologic complications seemed to correlate with periventricular and subcortical white matter changes. A strong correlation was found between CCT and SPECT periventricular white matter changes. Although the incidence of late neurologic toxicity following this rapid course of irradiation was high, clinical findings were less severe than expected, and all the patients were capable of self-care.
- Published
- 1998
- Full Text
- View/download PDF
36. Restoration of body composition in celiac children after one year of gluten-free diet.
- Author
-
Rea F, Polito C, Marotta A, Di Toro A, Iovene A, Collini R, Rea L, and Sessa G
- Subjects
- Anthropometry, Blood Proteins metabolism, Body Height, Body Weight, Bone Density, Child, Child, Preschool, Female, Hemoglobins analysis, Humans, Infant, Iron blood, Male, Nutritional Status, Triglycerides blood, Zinc blood, Body Composition, Celiac Disease diet therapy, Celiac Disease physiopathology, Glutens administration & dosage
- Abstract
Restoring protein, fat, and bone compartments in celiac children on a gluten-free diet (GFD) is not yet well understood. Hence, anthropometric, biochemical, and bone densitometric assessment was performed in 23 celiac children, 8 boys and 15 girls, aged 1 to 12 years (mean 4.7), at diagnosis and 1 year after GFD. At diagnosis the patients had height, arm muscle area, triceps skinfolds, subscapular skinfolds, fat area index, and bone mineral content significantly lower than in an age- and sex-matched control group. After 1 year on GFD, no significant difference was found between patients and controls in all the parameters studied except in height and arm muscle area, which, however, were very near to the normal expected. Serum hemoglobin, iron, and zinc values were below the normal range in more than one half of patients at diagnosis and within the normal range in almost all of them after 1 year of GFD. Serum hemoglobin, iron, zinc, triglycerides, proteins, albumin, and calcium values significantly rose during the year of GFD. A year of GFD in celiac children allows a virtually complete return in body mass composition.
- Published
- 1996
- Full Text
- View/download PDF
37. Postnatal dependence of plasma copper and zinc levels on gestational age and maturity observed in infants fed a high zinc content formula.
- Author
-
Di Toro R, Moro C, Perrone L, Rea F, Gialanella G, Grossi GF, and Moro R
- Subjects
- Body Height, Body Weight, Female, Humans, Infant, Newborn, Male, Zinc administration & dosage, Copper blood, Gestational Age, Infant Food, Infant, Premature, Infant, Small for Gestational Age, Zinc blood
- Abstract
We studied the effect of gestational age and maturity on plasma zinc and copper levels at 10 and 120 days of age. The association of plasma zinc changes and body growth was also investigated. Infants were receiving a controlled intake of zinc and copper solely through a zinc-supplemented formula (4.7 mg/L of zinc and 0.16 mg/L of copper). Twenty-eight low-birthweight infants (less than 2,500 g) having gestational ages ranging from 33 to 40 weeks [17 with an appropriate birthweight for gestational age (AGA) and 11 small for gestational age (SGA)] were enrolled in the present study. Measurements of plasma zinc and copper concentration, weight, length, head circumference, and tricipital and subscapular skinfolds were carried out at 10 and 120 days of age. Proton-induced x-ray fluorescence technique (PIXE) was used to assess copper and zinc concentrations. At 10 days of age a significant correlation between copper concentration and gestational age was found. At 120 days of age the copper concentration was higher than at 10 days and independent of gestational age and maturity (mean +/- SEM = 116 +/- 5 micrograms/dl). At 10 days of age no significant correlation between zinc content and gestational age was found (86 +/- 4 micrograms/dl). The plasma zinc percent change over the period from 10 to 120 days of age was positively correlated with gestational age in the whole sample as well as in AGA and SGA infants separately.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1985
- Full Text
- View/download PDF
38. CT demonstration of bilateral Castleman tumors in the mediastinum.
- Author
-
Fiore D, Biondetti PR, Calabró F, and Rea F
- Subjects
- Humans, Hyperplasia, Male, Middle Aged, Lymph Nodes pathology, Mediastinal Diseases diagnostic imaging, Tomography, X-Ray Computed
- Abstract
A case of bilateral Castleman tumors in the posterior mediastinum is described. Computed tomography proved to be an accurate, noninvasive method of investigation since it identified not only a large mass but also a smaller mass, which was not visible on standard chest X-ray film. Complete surgical excision was possible. The high attenuation values of both masses demonstrated the hypervascularity of the lesion.
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.